OHR Pharmaceutical Культура компании

Mr. Samuel Backenroth, also known as Sam, has been Chief Financial Officer at Ohr Pharmaceutical, Inc. and Vice President of Business Development since April 2010. Mr. Backenroth served as Interim Chief Financial Officer at Ohr Pharmaceutical, Inc since April 2010 to July 2012. Mr. Backenroth has executive experience in financing biotechnology companies and he most recently worked at The Benchmark Company LLC, an investment bank specializing in micro-cap biotechnology transactions. Mr. Backenroth graduated from Touro College with a bachelor's degree in finance.

Dr. Peter K. Kaiser, M.D. has been Head of Product Development at Ohr Pharmaceutical, Inc. since May 18, 2016. Dr. Kaiser served as Senior Vice President of Product Development at Ohr Pharmaceutical, Inc. since June 2, 2014. Dr. Kaiser is an internationally recognized vitreoretinal specialist and a leader in ophthalmic pharmaceutical development. In addition to being a cofounder of SKS Ocular LLC, Dr. Kaiser has been a Principal Investigator in over 50 trials evaluating new treatments for AMD, DR and other retinal disorders and Study Chairman of 7 major, multi-center, international clinical trials. Dr. Kaiser is a Founder and Director of Retinal Clinical Research Center and Digital Optical Coherence Tomography Reading Center (DOCTR) at The Cleveland Clinic's Cole Eye Institute. He is an Editor-in-Chief of Retinal Physician, Associate Editor of International Ophthalmology Clinics and serves on the editorial boards of American Journal of Ophthalmology, Retina, Retina Today and Ocular Surgery News. He has over 15 years of experience in preclinical and clinical development, regulatory submissions and post-approval sales and marketing. He has participated in the preparation of regulatory filings and presentations to the FDA for Regeneron and Thrombogenics. He serves on the scientific advisory boards of Bayer, Novartis, Genentech, GlaxoSmithKline, Allegro, Alcon, Allergan, Regeneron, Bausch and Lomb, Thrombogenics, Alimera, TargeGen, Oraya, ArcticDx, Sequenom, Ophthotech, Kanghong, Heidelberg Engineering and Carl Zeiss Meditec. Mr. Kaiser serves as a Member of Medical Advisory Board of Quark Pharmaceuticals, Inc. (formerly, Quark Biotech, Inc.). He is a National Institute of Health RO1 funded investigator and leads a team involved in the evaluation of vascular biology in age-related macular degeneration and diabetic retinopathy. He has authored six ophthalmology textbooks and more than 200 peer-reviewed papers. Dr. Kaiser served as a Member of Scientific Advisory Board of TearLab Corporation from December 2005 to November 1, 2007. Dr. Kaiser has been recognized by the American Academy of Ophthalmology and American Society of Retina Specialists with both Achievement and Senior Achievement Awards. He is the team ophthalmologist for the Cleveland Browns (National Football League) and Cleveland Cavaliers (National Basketball Association). Dr. Kaiser graduated magna cum laude with Highest Honors from Harvard College and magna cum laude from Harvard Medical School. He completed an internal medicine internship at Massachusetts General Hospital, an ophthalmology residency at the Massachusetts Eye and Ear Infirmary and a vitreoretinal fellowship at Bascom Palmer Eye Institute before joining the vitreoretinal department of the Cole Eye Institute at the Cleveland Clinic Foundation, Cleveland, Ohio where he is the Chaney Family Endowed Chair in Ophthalmology Research and vitreoretinal staff at Cole Eye Institute.

Dr. Marlene Modi, Ph.D., has been Head of Preclinical and Regulatory Affairs at Ohr Pharmaceutical, Inc., since May 18, 2016. Dr. Modi served as Vice President of Preclinical Development and Regulatory Affairs at Ohr Pharmaceutical, Inc. Dr. Modi serves as the Head of Clinical Development and Clinical Pharmacology at SKS Ocular, LLC. She served as a Vice President of Preclinical Development at Optherion, Inc. She has 25 years of experience in the pharmaceutical industry. Before joining Optherion Inc., she served as Senior Director of Clinical Pharmacology at Eyetech Pharmaceuticals, Inc. For the previous 15 years, Dr. Modi worked at Hoffmann-La Roche in key management positions, including Site Head and Director of Clinical Pharmacology. Dr. Modi has an extensive expertise in the areas of preclinical and clinical development of large molecules (e.g., proteins, monoclonal antibodies, aptamers and pegylated compounds). Her work has included the therapeutic areas of ophthalmology, virology, infectious disease, neurology, oncology, diabetes and asthma. Her areas of expertise include drug-drug interactions, pharmacokinetic-pharmacodynamic relationships and dose- and exposure-response relationships in special populations. Dr. Modi holds a B.S. in Pharmacy from the University of Houston and a Ph.D. in Pharmaceutics from the State University of New York at Buffalo.

Dr. Glenn L. Stoller, M.D., has been the Chief Scientific Officer at Ohr Pharmaceutical, Inc., since June 2, 2014. Dr. Stoller is a Partner of Ophthalmic Consultants of Long Island. He co-founded SKS Ocular, LLC in 2010 and served as its Chief Scientific Officer. He serves as an Advisor for a number of Pharmaceutical Companies, including Genentech and OSI Eyetech. He has extensive experience in the pre-clinical and clinical development of ocular therapeutic agents. Dr. Stoller served as the Head of Ocular Division of Lpath Inc. since April 2006. He serves as a Member of Scientific Advisory Board at Tyrogenex, Inc. He served as a Member of Advisory Board at Lpath Inc. He played a key role in establishing that bioactive lipids are mediators of human retinal disease. Dr. Stoller led Lpath Ocular and oversaw the preclinical and clinical development of iSONEP, from inception through a development and commercialization partnership with Pfizer. He led the non-GLP and IND enabling studies for iSONEP leveraging relationships with biotech companies, contract research organizations and academia. He was actively involved in all aspects of the iSONEP ocular program, including formulation, toxicology and CMC. He played a key role in the design and development of clinical protocols and presentation of the program to the FDA. He is a Member of the major medical organizations in his field including The Retina Society and The American Society of Retina Specialists. He is an Editorial Board Member of the American Academy of Ophthalmology, where he is the Sole Representative for The Macula Society. He is an Assistant Clinical Professor at New York Presbyterian Hospital (New York Weill Campus). He has lectured extensively. He has published numerous articles and book chapters. As a Principal Investigator, Pharmaceutical Industry Consultant and Scientific Advisory Board Member, he has participated in over 40 clinical trials for ocular diseases including wet age-related macular degeneration, dry age-related macular degeneration, diabetic retinopathy and retinal venous occlusive disease. Dr. Stoller has participated in all stages of preclinical and clinical development for therapeutics and devices as well as post-approval sales and marketing. He is a nationally recognized Retina Specialist, Medical Scientist and Innovator. He is a Practicing Eye Surgeon. Dr. Stoller is a Board Certified Ophthalmologist specializing in medical and surgical diseases of the retina, vitreous and macula and practices at Ophthalmic Consultants of Long Island in New York. He completed his fellowship in medical and surgical diseases of the retina at New York Presbyterian Hospital-Cornell Campus in New York City. Dr. Stoller graduated summa cum laude and Phi Beta Kappa from the University of Rochester with a degree in Neuroscience. Dr. Stoller received his Medical Degree from NYU School of Medicine, where he was awarded the Valentine Mott Medal for the medical student who has made the best contribution to clinical investigation in surgery. He completed his Ophthalmology Residency at the Harkness Eye Institute at Columbia University and a Vitreoretinal Fellowship at Weill Cornell Medical Center.